Mibecol

Ezetimibe, the active ingredient in Mibecol, is a cholesterol absorption inhibitor presented as a tablet for oral use. It treats hypercholesterolemia and related lipid disorders in adults.

GNH USA supplies Mibecol as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mibecol (ezetimibe) acts on the intestinal cholesterol absorption pathway and is indicated for several lipid disorders.

Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol levels. Primary hyperlipidemia: reduces elevated cholesterol and triglyceride concentrations. Homozygous familial hypercholesterolemia: provides LDL‑cholesterol reduction when other therapies are insufficient. Adjunct to statin therapy: enhances LDL‑cholesterol lowering when combined with a statin.

Ezetimibe is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Abdominal pain: mild to moderate discomfort in the stomach area. - Diarrhea: loose stools occurring intermittently. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate head pain. - Nausea: sensation of needing to vomit. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Cholestatic hepatitis: inflammation of the bile ducts that may lead to liver dysfunction. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Muscle toxicity: myopathy or rhabdomyolysis, especially when combined with statins. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and vomiting.

Before initiating therapy, clinicians should consider several safety measures.

Monitor liver function: check hepatic enzymes periodically. Assess lipid profile: evaluate baseline and follow‑up cholesterol levels. Evaluate for gallstones: avoid use in patients with active biliary disease. Use caution in hepatic impairment: dose adjustment may be required. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at ambient temperature: keep in the original pack, protect from moisture.

Ezetimibe may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Cholestyramine, colestipol, colesevelam: bind ezetimibe in the gut and markedly reduce absorption. - Cyclosporine: increases ezetimibe plasma concentrations, requiring monitoring. - Bile acid sequestrants: may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Statins: combined use can raise risk of myopathy; monitor muscle symptoms and CK levels. - Warfarin: ezetimibe may alter INR; check coagulation status regularly. - Antacids: may affect ezetimibe absorption; advise spacing of doses.